These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20582941

  • 21. [New oncological treatment principle with imatinib].
    Kuenen BC, Pinedo HM.
    Ned Tijdschr Geneeskd; 2003 Oct 18; 147(42):2044-5. PubMed ID: 14606348
    [Abstract] [Full Text] [Related]

  • 22. Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth.
    Suzuki D, Kobayashi R, Yasuda K, Yamamoto H, Morioka K, Mikawa M, Kobayashi K.
    J Pediatr Hematol Oncol; 2011 Oct 18; 33(7):e304-6. PubMed ID: 21941133
    [Abstract] [Full Text] [Related]

  • 23. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR.
    Int J Cancer; 2002 Aug 20; 100(6):623-6. PubMed ID: 12209598
    [Abstract] [Full Text] [Related]

  • 24. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD.
    J Clin Oncol; 2002 Sep 01; 20(17):3586-91. PubMed ID: 12202658
    [Abstract] [Full Text] [Related]

  • 25. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
    Mattox AK, Mehta AI, Grossi PM, Cummings TJ, Adamson DC.
    J Neurosurg; 2010 May 01; 112(5):965-77. PubMed ID: 19681684
    [Abstract] [Full Text] [Related]

  • 26. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C, Luo Z, Chen J, Zheng B, Zhang R, Chen Y, Shi Y.
    Medicine (Baltimore); 2015 May 01; 94(17):e773. PubMed ID: 25929918
    [Abstract] [Full Text] [Related]

  • 27. [Targeted therapy of dermatofibrosarcoma with imatinib].
    Ugurel S.
    J Dtsch Dermatol Ges; 2007 Mar 01; 5(3):261. PubMed ID: 17338806
    [No Abstract] [Full Text] [Related]

  • 28. [Clinical studies with imatinib in 2004].
    Eckhardt S.
    Orv Hetil; 2005 May 01; 146(18 Suppl 1):941-4. PubMed ID: 15921309
    [Abstract] [Full Text] [Related]

  • 29. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
    Llombart B, Sanmartín O, López-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistós JL, Almenar S, Llombart-Bosch A, Guillén C.
    Histopathology; 2009 Jun 01; 54(7):860-72. PubMed ID: 19635106
    [Abstract] [Full Text] [Related]

  • 30. Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible?
    Wang C, Luo Z, Zheng B, Chen Y, Cao X, Wang J, Zhang R, Shi Y.
    Eur J Cancer Prev; 2012 Nov 01; 21(6):585-7. PubMed ID: 23014697
    [No Abstract] [Full Text] [Related]

  • 31. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
    Savoia P, Ortoncelli M, Quaglino P, Bernengo MG.
    Dermatol Surg; 2006 Aug 01; 32(8):1097-102. PubMed ID: 16918576
    [No Abstract] [Full Text] [Related]

  • 32. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
    Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín O.
    Semin Diagn Pathol; 2013 Feb 01; 30(1):13-28. PubMed ID: 23327727
    [Abstract] [Full Text] [Related]

  • 33. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 01; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 34. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
    Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y.
    Br J Dermatol; 2004 Jul 01; 151(1):235-7. PubMed ID: 15270901
    [No Abstract] [Full Text] [Related]

  • 35. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
    Kallini JR, Khachemoune A.
    J Drugs Dermatol; 2014 Dec 01; 13(12):1474-7. PubMed ID: 25607791
    [Abstract] [Full Text] [Related]

  • 36. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
    McArthur GA.
    Curr Opin Oncol; 2006 Jul 01; 18(4):341-6. PubMed ID: 16721128
    [Abstract] [Full Text] [Related]

  • 37. Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions.
    Fernandez-Flores A.
    Rom J Morphol Embryol; 2007 Jul 01; 48(4):419-21. PubMed ID: 18060194
    [Abstract] [Full Text] [Related]

  • 38. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.
    Handolias D, McArthur GA.
    Future Oncol; 2008 Apr 01; 4(2):211-7. PubMed ID: 18407734
    [Abstract] [Full Text] [Related]

  • 39. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, Casali PG.
    Int J Cancer; 2011 Oct 01; 129(7):1761-72. PubMed ID: 21128251
    [Abstract] [Full Text] [Related]

  • 40. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
    Fattoruso SI, Visca P, Lopez M.
    Clin Ter; 2008 Oct 01; 159(5):361-7. PubMed ID: 18998038
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.